Shares of Sangamo Therapeutics (NASDAQ:SGMO) were transacted with a volume of 7031062 shares in last trading period as compared to its average volume of 2350.8K shares over last three months period. The stock price scored 6.02% and valued at $13.03.
Sangamo Therapeutics a USA based Company, belongs to Healthcare sector and Biotechnology industry. Shares of the company returned 43.34% during the last five trading days and it returned 29.27% in past 30 trading days. It changed 10.61% over recent three months. The stock has changed -26.80% in one year period and YTD Performance clocked at 13.50%.
Sangamo Therapeutics (NASDAQ:SGMO) reported that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being offered by Sangamo. In addition, Sangamo expects to grant the underwriters of the offering a 30-day option to purchase additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering will be completed, or as to the actual size or terms of the offering.
Sangamo anticipates using the net proceeds from the offering for working capital and other general corporate purposes, including support for its own and its partnered gene therapy, genome editing, cell therapy and gene regulation product candidates and research programs, its manufacturing facilities and other business development activities.
Cowen and Company, LLC, Wells Fargo Securities, LLC and Barclays Capital Inc. are acting as joint book-running managers for the offering.
The price moved ahead 33.94% from the mean of 20 days, 31.73% from 50 and separated 1.91% from 200 days average price. Its price volatility for a month is at 5.55% and for a week, volatility remained at 7.25%. It beta stands at 2.81. Company’s price to sales ratio for last 12 months was 15.77 while its price to book ratio for the most recent quarter was 3.64. Its Market Cap valued at $1332.57M.